Raclopride and chlorpromazine, but not clozapine, increase muscle rigidity in the rat: Relationship with D2 dopamine receptor occupancy

Neuropsychopharmacology

Volumn 21, Issue 1, 1999, Pages 101-109

  Hemsley, Kim M ^a   B app sci , ^a   Crocker, Ann D ^a   B sc , ^a  

^a FLINDERS UNIVERSITY   (Australia)

Author keywords

Antipsychotic drugs; Dopamine receptors; Muscle tone; Rat; Receptor occupancy

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; DOPAMINE 2 RECEPTOR; RACLOPRIDE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOSE RESPONSE; DRUG EFFECT; DRUG RECEPTOR BINDING; ELECTROMYOGRAM; MALE; MUSCLE RIGIDITY; MUSCLE TONE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR OCCUPANCY; SUBCUTANEOUS DRUG ADMINISTRATION; SUBSTANTIA NIGRA;

ANIMALS; ANTIPSYCHOTIC AGENTS; AUTORADIOGRAPHY; BRAIN CHEMISTRY; CHLORPROMAZINE; CLOZAPINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROMYOGRAPHY; HINDLIMB; MALE; MUSCLE RIGIDITY; MUSCLE TONUS; RACLOPRIDE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D2; SALICYLAMIDES;

EID: 0344655619     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(99)00010-X     Document Type: Article

References (32)

1. Ayd F.J. A survey of drug-induced extrapyramidal reactions. JAMA. 175:1961;1054-1060.
2. Barnes D.E., Robinson B., Csernansky J.G., Bellows E.P. Sensitisation versus tolerance to haloperidol-induced catalepsy. Multiple determinants Pharmacol Biochem Behav. 36:1990;883-887.
3. Casey D.E. Clozapine. Neuroleptic induced extrapyramidal side effects and tardive dyskinesia Psychopharmacology. 99(Suppl.):1989;S47-S53.
4. Creese I., Burt D.R., Snyder S.H. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science. 192:1976;481-483.
5. Crocker A.D. A new view of the role of dopamine receptors in the regulation of muscle tone. Clin Exp Pharmacol Physiol. 22:1995;846-850.
6. Crocker A.D. The regulation of motor control. An evaluation of the role of dopamine receptors in the substantia nigra Rev Neurosciences. 8:1997;55-76.
7. Double K.L., Crocker A.D. Quantitative electromyographic changes following modification of central dopaminergic transmission. Brain Res. 604:1993;342-344.
8. Double K.L., Crocker A.D. Dopamine receptors in the substantia nigra are involved in the regulation of muscle tone. Proc Natl Acad Sci USA. 92:1995;1669-1673.
9. Ellenbroek B., Klockgether T., Turski L., Schwarz M. Distinct sites of functional interaction between dopamine, acetylcholine and γ-aminobutyrate within the neostriatum. An electromyographic study in rats Neuroscience. 17:1986;79-88.
10. 2 receptor occupancy by PET Psychopharmacology. 94:1988;1-7.
11. Farde L., Nördström A.-L. PET analysis indicates atypical central dopamine receptor occupancy in clozapine-treated patients. Br J Psychiatry. 160(Suppl 17):1992;30-33. a.
12. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Arch Gen Psychiatry. 49:1992;538-544. b.
13. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects Arch Gen Psychiatry. 49:1992;538-544. c.
14. Hacksell U., Jackson D.M., Mohell N. Does the dopamine receptor subtype selectivity of antipsychotic agents provide useful leads for the development of novel therapeutic agents? Pharmacol Toxicol. 76:1995;320-324.
15. 2 receptors by antipsychotic drugs. Proc Aust Soc Clin Exp Pharmacol Toxicol. 3:1996;81.
16. 2 receptor occupancy in the striatum and substantia nigra. Proc Aust Soc Clin Exp Pharmacol Toxicol. 4:1997;20.
17. Hemsley K.M., Crocker A.D. The effects of an irreversible dopamine receptor antagonist, N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ), on the regulation of muscle tone in the rat. The role of the substantia nigra Neurosci Lett. 251:1998;77-80.
18. Hoge S.K., Appelbaum P., Lawlor T., Beck J.C., Litman R., Greer A., Gutheil T.G., Kaplan E. A prospective multicenter study of patients' refusal of antipsychotic drugs. J Clin Psychiatry. 55:1990;29-35.
19. Kane J., Honingfeld G., Singer J., Meltzer H. Clozapine for the treatment of drug resistant schizophrenia. Arch Gen Psychiatry. 45:1988;789-796.
20. 2 receptors in the rat brain. Biochem Pharmacol. 34:1985;2251-2259.
21. 2 receptors Psychopharmacology. 112:1993;S40-S54.
22. McCreadie R.G. A double-blind comparison of raclopride and haloperidol in the acute phase of schizophrenia. Acta Psychiatr Scand. 86:1992;391-398.
23. 2 pKi values. J Pharmacol Exp Ther. 251:1989;238-246.
24. Nördstrom A.-L., Farde L., Wiesel F.A., Forslund K., Pauli S., Halldin C., Uppfeldt G. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects. A double-blind PET study of schizophrenic patients Biol Psychiatry. 33:1993;227-235.
25. 2 dopamine receptor occupancy and plasma antipsychotic drug levels in man. Int Clin Psychopharmacology. 10(Suppl 3):1995;81-85.
26. Robertson G.S., Fibiger H.C. Neuroleptics increase c-fos expression in the forebrain. Contrasting effects of haloperidol and clozapine Neuroscience. 46:1992;315-328.
27. 2-dopamine receptor occupancy differs between patients with and without extrapyramidal side effects. Acta Psychiatr Scand. 90:1994;266-268.
28. Schotte A., Janssen P., Megens A.A., Leysen J. Occupancy of central neurotransmitter receptors by risperidone, clozapine and haloperidol, measured ex vivo by quantitative autoradiography. Brain Res. 632:1993;191-202.
29. Seeman P., Lee T., Wong M., Wong K. Antipsychotic doses and neuroleptic/dopamine receptors. Nature. 261:1976;717-718.
30. Stockmeier C., DiCarlo J., Zhang Y., Thompson P., Meltzer H. Characterization of typical and atypical antipsychotic drugs based on in vivo occupancy studies of serotonin2 and dopamine 2 receptors. J Pharmacol Exp Ther. 266:1993;1374-1384.
31. 2 receptor occupancy rates by haloperidol and clozapine in vivo. Jpn J Psychiatry Neurology. 47:1993;131-137.
32. 2 receptor occupancy. Neuropsychopharmacology. 12:1995;57-64.